Scleroderma (systemic sclerosis or SSc) is a connective tissue disease of unknown cause, characterized by skin and visceral organs fibrosis and microvascular abnormalities. The prevalence of these patients is relatively low with 50-300 cases per 1 million population and the incidence of 2.3-22.8 cases per 1 million population per year. The risk for women is higher than men with a ratio of 3:1 and majority age 30-50 years. Diagnosis is based on clinical features and investigations. Management in patients to reduce or eliminate complaints and improve organ function but cannot cure patients.Case: Reported a case of diffuse cutaneous sitstemic scleroderma (dcSSc) with secondary infection in a 25-yearold woman. Diagnosis is based on American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria which include serological components. Furthermore, an assessment of disability and function of the patient is performed using the Scleroderma Health Assessment Questionnaire (SHAQ). Treatment for the skin using topical antibiotic and vaseline album. Whereas the systemic treatment with vasodilators, immunosuppressive, antifibrotic, and proton pump inhibitors.